Trial Profile
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Losartan (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Jan 2023 Results comparig the R0 resection rate on each of Arms 2 and 3 independently versus Arm 1 at a one-sided 0.10 level in borderline resectable and locally advanced pancreatic ductal adenocarcinoma presented at the 2023 Gastrointestinal Cancers Symposium
- 07 Sep 2022 Planned End Date changed from 31 Dec 2025 to 1 Jun 2027.
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.